All News
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6
Links:
Dr. John Cush RheumNow ( View Tweet)
Secukinumab promise in PMR is real
GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj
Dr. John Cush RheumNow ( View Tweet)
Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet
🔴Performance tests (SPPB)
were associated with
🔴Global functioning and health (ASAS-HI and other PROs)
What does this mean?
Improving physical performance could enhance PROs & QOL
#EULAR2025
POS#
@RheumNow
@XBaraliakos https://t.co/P3Q5NDvtoj
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#D2M_axSpA_saga 🇬🇷
Prevalence of D2M axSpA in 395 patients: 10.1%
Associated factors:
🔹️High disease activity at diagnosis
🔹️Comorbidities (high BMI, smoking, depression)
🔹️Unemployment
Kougkas et al.
POS#0121
#EULAR2025
@rheumnow https://t.co/vcPcTATTx5
Nelly ZIADE 🍀 Nellziade ( View Tweet)
What's the difference between PIPsA & NIPsA?
(Persistent Inflammatory confirmed by IMAGING
vs. Non inflammatory PsA)
🔹️Cross-sectional study
🔹️517 pts under b/tsDMARDs
🔹️10.3% D2T
🔹️57% PIPsA / 43% NIPsA
👇 Distinct phenotypes 👇
OP0176
#EULAR2025
@rheumnow https://t.co/YGHpbeE6ws
Nelly ZIADE 🍀 Nellziade ( View Tweet)
What happens to the prevalence of D2T PsA if we use different parameters in its definition?
Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)!
OP0177
#EULAR2025
@rheumnow https://t.co/QbF15t3Zrz
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🚨Diagnostic delays are real in axSpA:
-Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA.
-Increases disease burden and productivity losses.
-EMMs can present before articular sx
-Uveitis and IBD associated with longer dx delays.
-Diagnosis has improved since https://t.co/rWMwG7Ewwe
Links:
Adela Castro AdelaCastro222 ( View Tweet)
#guidelines everywhere
@jeffsparks presents points of interest from #ACR #ILD #recommendations
- a joint venture with American College of Chest Physicians
While simultaneously the EULAR ILD recommendations are being unveiled!
@RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9
Links:
Janet Pope Janetbirdope ( View Tweet)
A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Late-Onset Disease: Different Age, Different Rules?
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/Txvr62UpWZ
Dr. John Cush RheumNow ( View Tweet)
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Links:
Janet Pope Janetbirdope ( View Tweet)
In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment?
@RheumNow #EULAR2025 #OP0330
Mrinalini Dey DrMiniDey ( View Tweet)
Some RA-ILD is less of a worry, some is critical. How do we stratify?
Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6.
We need to do this more, so we can go really hard early when we need to.
#EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2
David Liew drdavidliew ( View Tweet)
🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity:
💶Cost =barrier in 🇳🇱
⛈️Weather =barrier in 🇹🇷
🧑⚕️HCP support =key in 🇫🇷
🏃Active transport & knowledge =enablers in 🇨🇭
Tailored physical activity interventions needed.
@RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7
Mrinalini Dey DrMiniDey ( View Tweet)
We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs:
- lower inflamm
- higher comorbidities
Doesn’t necessarily map to fibromyalgia dx
Beyond Rx, this is the critical question
CareRA/2000
#EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb
Links:
David Liew drdavidliew ( View Tweet)
